ARGs
The relative abundance of ARGs in samples from the SHIME model were assessed at seven different time points (Fig. 1), which included samples collected after stabilization of SHIME setup for two weeks and before administration of antibiotics (Control), samples collected after the administration of a gradient of combined antibiotics with each dose for one week (AmxGen), samples collected after the after the discontinuance of antibiotics for two weeks, administration of B. longum for two weeks, and administration of B. longum and inulin for two weeks (Recovery).
As shown in Fig. 2, a total of 52 targets ARGs were detected from different group samples using a high-throughput-qPCR (HT-qPCR) technique. The heatmap showed that the relative abundances of ARGs such as aminoglycoside, beta-lactam, and multidrug resistance genes were noticeably higher in the antibiotics exposure group as compared to the control group, while the tetracycline resistance genes were lower than control. For instance, the relative log abundance of ant2ia (aminoglycoside), bl2b_tem1 (beta-lactam), and qacedelta1 (multidrug) were 1.8, 1.6 and 1.7 log units higher after combined antibiotics treatment (AmxGen_1000A) than in control (Control_A2). However, tetb and tetw (tetracycline) were 1.3 and 1.7 log units lower than the control group. After two weeks of natural recovery, probiotics or synbiotics treatment, the relative abundances of these ARGs genes were restored, and probiotics B. longum provided a better recovery effect. For example, the log abundances of ant2ia (aminoglycoside), bl2b_tem1 (beta-lactam), and qacedelta1 (multidrug) were just 0.3–0.5 log units higher in BifidobacteriumR_A than Control_A2, and tetb and tetw (tetracycline) were just 0.3–0.4 log units lower than control group.
Human disease-related pathways
The metagenomics study of the 16S rRNA gene sequence by PICRUSt revealed the gene numbers of human disease-related functional pathways in the bacterial communities of the three groups, and the genes were presented in the heatmap (Fig. 3). The heatmap showed that the gene numbers of human disease-related pathways, including cancers, drug resistance, endocrine and metabolic diseases, infectious diseases, and neurodegenerative diseases were more abundant in high dose antibiotics treatment samples than that in control group. For instance, the gene numbers of bladder cancer, cationic antimicrobial peptide resistance, insulin resistance, pertussis, and amyotrophic lateral sclerosis in the AmxGen_1000A sample were 1.5–1.7 times as that of the Control_A2 sample. After two weeks of natural recovery, probiotics or synbiotics treatment, the numbers of these genes were decreased. Natural recovery could provide a good recovery effect (these genes in AmxGen_1000A were 1.5–1.7 times as that of NatureR_A), while probiotics B. longum caused these genes much lower (these genes in AmxGen_1000A were 2.2–2.4 times as that of BifidobacteriumR_A).
Microbiota community composition
In this study, the effects of antibiotics treatment on gut microbial communities’ composition were also investigated. Based on the 16S rRNA gene sequence analysis, the most abundant taxonomic groups assigned at the phylum level were Proteobacteria, Bacteroidetes, Firmicutes, and Fusobacteria, which account for 86.4–99.9% of the total gut microbiota (Fig. 4a). After combined amoxicillin and gentamicin exposure treatment with low dose, the abundances of Bacteroides (from 15.7–25.1% to 16.6–27.3%) and Fusobacterium (from 1.8–5.3% to 11.5–18.7%) increased, while the abundances of Proteobacteria (from 60.8–68.1% to 45.2–63.6%) and Firmicutes (from 3.5–6.1% to 0.6–2.3%) decreased. However, after high dose antibiotics treatment, the abundance of Proteobacteria increased significantly (from 65.5–68.1–98.5%), while the abundances of Bacteroides (from 22.0-25.1–1.1%), Firmicutes (from 4.9–6.1–0.2%) and Fusobacteria (from 1.8–0.1%) decreased, which was more obvious in sample from ascending colon. Compared with natural recovery, prebiotics or synbiotics treatment provided a better recovery effect. Obvious decrease in the abundance of Proteobacteria (from 69.5–82.4% to 55.0-59.1%), and increase in abundances of Bacteroidetes (from 8.9–17.9% to 20.2–26.9%) and Firmicutes (from 1.9–5.6% to 4.3–21.9%) were seen after prebiotics or synbiotics treatment.
The abundance of bacteria at the genus level also showed distinct changes (Fig. 4b). After exposure to low concentration of amoxicillin and gentamicin, the abundance of Klebsiella reduced (from 21.6–53.1% to 16.0-24.5%). However, after high dose antibiotics treatment, the abundance of Klebsiella significantly increased (from 44.8–53.1–73.7%), while the abundance of Bacteroides decreased (from 18.2–20.8–1.0%), which was also more obvious in sample from ascending colon. After two weeks of natural recovery, probiotics or synbiotics treatment, the abundances of these bacteria were recovered. The abundance of Klebsiella decreased (from 73.7% to 40.6–42.8%), while the abundance of Bacteroides increased (from 1.0% to 14.9–20.2%).
The linear discriminant analysis effect size (LEfSe) comparison analysis between the three groups is shown in Fig. S1. LEfSe analysis indicated that antibiotics exposure resulted in a significant decrease in the abundance of Cloacibacillus (LDA = 4.04), accompanied by a significant increase in Escherichia/Shigella (LDA = 3.99). After two weeks of natural recovery, probiotics or synbiotics treatment, the abundance of several genera increased significantly, including Anaeroglobus (LDA = 4.20), Phascolarctobacterium (LDA = 4.23), and Selenomonas (LDA = 4.60).
Microbiota diversity
Meanwhile, the fecal microbiota of alpha diversity was assessed. The taxon richness (Chao1 index), evenness (Simpson index), and diversity (Shannon index) are shown in Fig. S2. Compared with the control group, combined antibiotics exposure caused no significant difference in the microbial richness (Chao1, P = 0.913, T test), evenness (Simpson, P = 0.859, T test), and diversity (Shannon, P = 0.667, T test). Besides, alpha diversity of the recovery microbial community still showed no difference from the control (Chao1, P = 0.731, T test; Simpson, P = 0.955, T test; Shannon, P = 0.937, T test). However, the beta diversity of the microbiota communities was affected by antibiotics treatment. As shown in Fig. S3, the beta diversity results suggested that all the samples collected after combined antibiotics exposure differed from the control group, and sample AmxGen_1000A is much far away from the control group. Fig. S3 also showed that the differences still exist after two weeks of natural recovery, probiotics or synbiotics treatment. It can be seen that the ascending colon sample recovered better under natural condition, while the descending colon sample recovered better after probiotics treatment as these samples were closer to the control group.
Correlations between microbial taxa and ARGs or human disease-related pathways
The network analysis of co-occurrence patterns between the microbial taxa and the ARG subtypes is shown in Fig. 5. It was seen that Escherichia/Shigella (significantly enriched bacteria after antibiotics treatment) was positively associated with beta-lactam and multidrug resistance genes. For example, the correlation coefficients of Escherichia/Shigella with bl1_ec, baca, and tolc were about 0.98 (P < 0.05). Cloacibacillus, the significantly decreased bacterial genus in antibiotics treatment group, was also positively associated with several ARGs. For example, the strong correlations were found in Klebsiella with yidy/mdtl, teta, and aac3iia (r = 0.8–0.85, P < 0.01).
Figure 6 shows the results of co-occurrence patterns between the microbial taxa and human disease-related pathways. A very similar pattern of results was observed that significantly increased bacteria Klebsiella and Escherichia/Shigella after antibiotics treatment were positively associated with most of those human disease-related pathways. Specifically, the correlation coefficients of Klebsiella with cationic antimicrobial peptide resistance, pertussis, and Salmonella infection were about 0.92 (P < 0.001) and that of Escherichia/Shigella with colorectal cancer, viral myocarditis and toxoplasmosis were 0.89 (P < 0.001).